Skip to content

Alto Neuroscience ANRO Free cash flow yield

Free cash flow yield at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-5.5%-1.2pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
5.5%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-5.4%-2.2pp
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
-3.1%-1.4pp
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-18.3%-6.3pp
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-0.8%-0.3pp

Other financials

Income statement

See full
Operating income-$27.1M-73.1%
Net income-$26.2M-73.0%
EPS (diluted)-$0.80-42.9%

Balance sheet

See full
Cash & equivalents$264.3M+63.9%
Total debt$20.9M-17.2%
Total equity$243.4M+75.0%
Total assets$276.3M+60.7%

Cash flow

See full
Operating cash flow-$27.1M-63.6%
CapEx$556.0K+2,217%
Free cash flow-$27.6M-66.7%

Valuation

See full
Market cap$874.19M+1,358%
Enterprise value$630.81M-958%

Returns & leverage

See full
Return on equity-38.9%+0.9pp
Debt / equity0.1×-0.1×
Current ratio20.5×-2.0×

Where this comes from

Calculated from Alto Neuroscience’s reported figures.

Based on trailing twelve months.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alto Neuroscience's free cash flow yield?
Alto Neuroscience (ANRO) reported free cash flow yield of -8.8% in Q1 2026.
How has Alto Neuroscience's free cash flow yield changed year-over-year?
Alto Neuroscience's free cash flow yield increased by 90.7% year-over-year, from -93.8% to -8.8%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.